Active, not recruitingPhase 1NCT04521686
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Studying Rare malignant epithelial tumor of liver and intrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eli Lilly and Company
- Principal Investigator
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Eli Lilly and Company
- Intervention
- LY3410738(drug)
- Enrollment
- 200 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (30)
- Mayo Clinic of Scottsdale, Phoenix, Arizona, United States
- The University of Arizona Cancer Center, Tucson, Arizona, United States
- USC Norris Cancer Hospital, Los Angeles, California, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- University of Chicago Pritzker School of Medicine, Chicago, Illinois, United States
- Indiana University School of Medicine, Indianapolis, Indiana, United States
- The John Hopkins Hospital, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Memorial Sloan Kettering Cancer Center, Middletown, New Jersey, United States
- Memorial Sloan Kettering Cancer Center, Commack, New York, United States
- Memorial Sloan Kettering Cancer Center, Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Sarah Cannon Cancer Center, Nashville, Tennessee, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04521686 on ClinicalTrials.govOther trials for Rare malignant epithelial tumor of liver and intrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06990659Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)University Hospital, Angers
- RECRUITINGPHASE2NCT07146646Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract CancerCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06529718Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer PatientsUNICANCER
- RECRUITINGNCT07151118ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract CancerCHA University
- RECRUITINGNCT07142226Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTCCHA University
- RECRUITINGPHASE2NCT07135544A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract CancerYongjun Chen
- RECRUITINGNCT06793709A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After ChemotherapyEisai Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06708663HX009+ IN10018 with or Without Standard Chemotherapy for Advanced Solid TumoursHangzhou Hanx Biopharmaceuticals, Ltd.
See all trials for Rare malignant epithelial tumor of liver and intrahepatic biliary tract →